Patents Assigned to Lophora ApS
  • ACID ADDITION SALTS OF (S)-3-(2,5-DIMETHOXY-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE AND (S)-3-(2-METHOXY-5-(METHYLTHIO)-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE, SPECIFIC POLYMORPHS THEREOF AND METHODS FOR THEIR MANUFACTURE
    Publication number: 20240208903
    Abstract: The present invention relates to certain pharmaceutically acceptable salts of (S)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (S)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl) phenyl)piperidine and specific polymorphs thereof. More particularly, the present invention relates to the compounds of Formula (VI) as well as chemical routes for their manufacture.
    Type: Application
    Filed: May 5, 2022
    Publication date: June 27, 2024
    Applicant: LOPHORA APS
    Inventors: Jesper Langgaard KRISTENSEN, Emil MÄRCHER-RØRSTED
  • 5-HTagonists for use in treatment of depression
    Patent number: 11642336
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: May 9, 2023
    Assignee: LOPHORA APS
    Inventors: Jesper Langgaard Kristensen, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HT2A agonists for use in treatment of depression
    Patent number: 11633390
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: April 25, 2023
    Assignee: LOPHORA APS
    Inventors: Jesper Langgaard Kristensen, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
    Publication number: 20220062257
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Application
    Filed: June 16, 2021
    Publication date: March 3, 2022
    Applicant: Lophora ApS
    Inventors: Jesper Langgaard KRISTENSEN, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HTagonists for use in treatment of depression
    Patent number: 11246860
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: February 15, 2022
    Assignee: Lophora ApS
    Inventors: Jesper Langgaard Kristensen, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
    Publication number: 20210330658
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Application
    Filed: July 6, 2021
    Publication date: October 28, 2021
    Applicant: Lophora ApS
    Inventors: Jesper Langgaard KRISTENSEN, Anders Asbjørn JENSEN, Emil MÄRCHER-RØRSTED, Sebastian LETH-PETERSEN
  • 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
    Publication number: 20210137908
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Application
    Filed: November 5, 2020
    Publication date: May 13, 2021
    Applicant: Lophora ApS
    Inventors: Jesper Langgaard KRISTENSEN, Anders Asbjørn JENSEN, Emil MÄRCHER-RØRSTED, Sebastian LETH-PETERSEN